All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 78 points (-0.5%) at 16,015 as of Monday, Jan. 25, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 648 issues advancing vs. 2,316 declining with 132 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is down 0.6%. A company within the industry that fell today was

Regeneron Pharmaceuticals

(

REGN

), up 1.4%. Top gainers within the industry include

Valeant Pharmaceuticals International

(

VRX

), up 5.2%,

Ionis Pharmaceuticals

(

IONS

), up 4.0%,

Biomarin Pharmaceutical

(

BMRN

), up 2.0%,

AstraZeneca

(

AZN

), up 1.2% and

Novo Nordisk A/S

(

NVO

), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Alexion Pharmaceuticals

(

ALXN

) is one of the companies pushing the Drugs industry lower today. As of noon trading, Alexion Pharmaceuticals is down $1.20 (-0.8%) to $157.96 on light volume. Thus far, 388,222 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $156.80-$160.15 after having opened the day at $156.80 as compared to the previous trading day's close of $159.15.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $35.0 billion and is part of the health care sector. Shares are down 16.6% year-to-date as of the close of trading on Friday. Currently there are 13 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates

Alexion Pharmaceuticals

as a

hold

TheStreet Recommends

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

Alexion Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Bristol-Myers Squibb Company

(

BMY

) is down $0.76 (-1.2%) to $63.64 on light volume. Thus far, 1.9 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $63.42-$64.42 after having opened the day at $64.23 as compared to the previous trading day's close of $64.40.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $105.3 billion and is part of the health care sector. Shares are down 6.4% year-to-date as of the close of trading on Friday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Bristol-Myers Squibb Company

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Bristol-Myers Squibb Company Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Merck

(

MRK

) is down $0.36 (-0.7%) to $50.99 on light volume. Thus far, 2.8 million shares of Merck exchanged hands as compared to its average daily volume of 10.7 million shares. The stock has ranged in price between $50.76-$51.44 after having opened the day at $51.35 as compared to the previous trading day's close of $51.35.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $142.2 billion and is part of the health care sector. Shares are down 2.8% year-to-date as of the close of trading on Friday. Currently there are 8 analysts that rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels, compelling growth in net income and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).